IL17A and infection: In our studies, intranasal administration of α-IL-17 antibodies only modestly enhanced peak bacterial growth in the airways and did not delay clearance of the infection, although this treatment did inhibit KC gene expression and neutrophil recruitment to the airways in response to B. pertussis infection.